Exposure keratitis

Summary

Exposure keratitis (MONDO:0004794) is a disease and 1 clinical trial. A subtype of keratoconjunctivitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	exposure keratitis
Mondo ID	MONDO:0004794
DOID	DOID:9461
ICD-10-CM	H16.21
ICD-11	1261495652
SNOMED CT	14366000
UMLS	C0339295
MedGen	87383
Is cancer (heuristic)	no

Also known as: exposure keratoconjunctivitis

Disease family

This is a subtype of keratoconjunctivitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › corneal disorder › keratitis › keratoconjunctivitis › exposure keratitis

Related subtypes (6): phlyctenulosis, neurotrophic keratoconjunctivitis, punctate epithelial keratoconjunctivitis, epidemic keratoconjunctivitis, dry eye syndrome, superior limbic keratoconjunctivitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06539663	PHASE2/PHASE3	COMPLETED	The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients